Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA; Genetics Division, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute and Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Cell Metab. 2019 May 7;29(5):1017-1019. doi: 10.1016/j.cmet.2019.04.008.
CTNNB1, encoding β-catenin, is frequently mutated in hepatocellular carcinoma, the most rapidly growing solid cancer in the US, and activating mutations in this gene are associated with increased expression of glutamine synthetase. A new report by Adebayo Michael et al. (2019) identifies mTOR as a direct target of WNT/β-catenin signaling through increased production of glutamine, which is required for the carcinogenic effects of WNT/β-catenin activity in the liver.
CTNNB1 编码 β-连环蛋白，在肝细胞癌中经常发生突变，这是美国增长最快的实体瘤，该基因的激活突变与谷氨酰胺合成酶的表达增加有关。Adebayo Michael 等人的一项新报告 (2019) 通过增加谷氨酰胺的产生，确定 mTOR 为 WNT/β-连环蛋白信号的直接靶点，这是 WNT/β-连环蛋白在肝脏中的致癌作用所必需的。
